» Articles » PMID: 33994738

????-Catenin-a Possible Prognostic Molecular Marker for Recurrence in Histopathologically Negative Surgical Margin of Oral Cancer

Overview
Specialty Oncology
Date 2021 May 17
PMID 33994738
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The locoregional recurrence in oral cancer is not predicted by the histopathological parameters solely as the normal morphological looking cells harbor the genomic instability which acts as the potential tumor cells for recurrence in future. Therefore, there is an urgent need of the biomarker for prognostic stratification of patients with high risk of disease recurrence and appropriate management. Eighty oral squamous cell carcinoma (OSCC) patients were included in the study during the period 2012 to 2014 at Apollo Hospitals and Kalinga Institute of Medical sciences, Bhubaneswar. OSCC tissue samples were collected at the time of surgical excision, and immunohistochemistry (IHC) was performed to check the expression of -catenin in cut margin (CM) and tumor. Statistical analysis was carried out using SPSS based on clinical and pathological records. It was observed that among 80 patients, 33.75% (27 patients) developed recurrence. The recurrence rate was low for 6 out of 27 patients (22.2%) where -catenin is positive in tumor and negative in cut margin, while it was quite high in 21 out of 27 (77.8%) when marker is negative in tumor but positive in cut margin (CM). The odds of recurrence among patients having high levels of ????-catenin in CM was 3.6 times higher than the odds of recurrence among patients having lower levels of ????-catenin in CM ( < 0.017). In conclusion, this study highlighted that ????-catenin can be included as a prognostic molecular marker, along with routine histopathological study to influence therapeutic decisions and appropriate management of disease.

Citing Articles

Comparative evaluation of Fascin-1 with clinicopathological parameters and recurrence in oral squamous cell carcinoma.

Saify F, Chaudhary M, Tiwari N, Jain S, Deb Sikhdar S, Sood M J Oral Maxillofac Pathol. 2025; 28(4):555-559.

PMID: 39949678 PMC: 11819638. DOI: 10.4103/jomfp.jomfp_146_24.


Prognostic and Clinicopathological Significance of the Aberrant Expression of β-Catenin in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

Ramos-Garcia P, Gonzalez-Moles M Cancers (Basel). 2022; 14(3).

PMID: 35158747 PMC: 8833491. DOI: 10.3390/cancers14030479.

References
1.
Iwai S, Yonekawa A, Harada C, Hamada M, Katagiri W, Nakazawa M . Involvement of the Wnt-β-catenin pathway in invasion and migration of oral squamous carcinoma cells. Int J Oncol. 2010; 37(5):1095-103. DOI: 10.3892/ijo_00000761. View

2.
Park B, Chiosea S, Grandis J . Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark. 2011; 9(1-6):325-39. PMC: 3409637. DOI: 10.3233/CBM-2011-0163. View

3.
Rampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A . Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Ann Oncol. 2013; 24(8):2124-31. DOI: 10.1093/annonc/mdt013. View

4.
Padhi S, Roy S, Kar M, Saha A, Roy S, Adhya A . Role of CDKN2A/p16 expression in the prognostication of oral squamous cell carcinoma. Oral Oncol. 2017; 73:27-35. DOI: 10.1016/j.oraloncology.2017.07.030. View

5.
Shiah S, Shieh Y, Chang J . The Role of Wnt Signaling in Squamous Cell Carcinoma. J Dent Res. 2015; 95(2):129-34. DOI: 10.1177/0022034515613507. View